Pharmacogenetics of Drug Transporters

Pharmacogenetics and Individualized Therapy

Volumn , Issue , 2012, Pages 101-148

  Meyer zu Schwabedissen, Henriette E ^a   Grube, Markus ^a   Kroemer, Heyo K ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Drug transporter pharmacogenetics; Pharmacogenetics of efflux transporters; Pharmacogenetics, genetic variations of interindividual differences; Transporters, for drug disposition and efficacy; Uptake transporter pharmacogenetics

Indexed keywords

EID: 84886071325     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118116494.ch4     Document Type: Chapter

References (325)

1. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006;57:119-137.
2. Wilkinson GR. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 2005;352(21):2211-2221.
3. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447(5):653-665.
4. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 1999;274(24):17159-17163.
5. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 2000;278(1):G156-G164.
6. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001;120(7):1689-1699.
7. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology 2006;130(6):1793-1806.
8. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl- CoA reductase inhibitor transporters. J. Biol. Chem. 1999;274 (52):37161-37168.
9. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 2005;15(7):513-522.
10. Kopplow K, Letschert K, Konig J, Walter B, Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 2005;68 (4):1031-1038.
11. Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 2007;35 (8):1308-1314.
12. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 2001;276(38):35669-35675.
13. Tirona RG, Leake BF, Podust LM, Kim RB. Identification of amino acids in rat pregnaneX receptor that determine species-specific activation. Mol. Pharmacol. 2004;65(1):36-44.
14. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 2002;302(2):804-813.
15. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004;14(11):749-757.
16. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14(7):429-440.
17. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics 2007;17(8):647-656.
18. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003;73(6):554-565.
19. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 2004;75 (5):415-421.
20. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 2005;78(4):342-350.
21. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 2007;82(5):541-547.
22. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 2006;16 (12):873-879.
23. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 2008;83 (2):251-257.
24. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 2007;82(6):726-733.
25. Kalliokoski A, Backman J, Kurkinen K, Neuvonen P, Niemi M. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. Clin. Pharmacol. Ther. 2008;84(4):488-96.
26. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 2006;79(5):427-439.
27. Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 2008;9(9):1217-1227.
28. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9(1):19-33.
29. Gerloff T, Schaefer M, Mwinyi J, Johne A, Sudhop T, Lutjohann D, et al. Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn. Schmiedebergs Arch. Pharmacol. 2006;373(1):45-50.
30. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther. 2006;79(5):419-426.
31. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, et al. SLCO1B1 521T-- H C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol. 2007;64 (3):346-352.
32. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. New Engl. J. Med. 2008;359 (8):789-799.
33. Furihata T, Satoh N, Ohishi T, Ugajin M, Kameyama Y, Morimoto K, et al. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T H G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J. 2009;9(3):185-193.
34. Werner D, Werner U, Meybaum A, Schmidt B, Umbreen S, Grosch A, et al. Determinants of steady-state torasemide pharmacokinetics: Impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin. Pharmacokinet. 2008;47(5):323-332.
35. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 2005;77(6):468-478.
36. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br. J. Clin. Pharmacol. 2008;66(6):818-825.
37. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. 2005;59(5):602-604.
38. Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol. 2006;62 (5):567-572.
39. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl- 10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 2005;33(3):434-439.
40. Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, et al. Lifethreatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother. Pharmacol. 2000;63 (6):1165-1169.
41. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 2001; 276(13):9626-9630.
42. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. Role of organic aniontransporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placentamaternal liver tandem excretory pathway for foetal bilirubin. Biochem. J. 2003;371(Pt 3):897-905.
43. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin. Cancer Res. 2008;14(11):3312-3318.
44. Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San Martin F, Marin JJ. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem. Pharmacol. 2006;72(6):729-738.
45. Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001;121(5):1185-1190.
46. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120(2):525-533.
47. Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14(7):441-452.
48. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab. Dispos. 2006;34(7):1109-1115.
49. Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, et al. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab. Dispos. 2008;36(4):796-805.
50. Miura M, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T. Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin. Chim. Acta. 2009;399(1-2):83-87.
51. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. 2005; 4(8):815-818.
52. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, et al. Variants in the SLCO1B3 gene: Interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther. 2007;81(1):76-82.
53. Baker S, Verweij J, Cusatis G, van Schaik R, Marsh S, Orwick S, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 2009;85(5):155-163.
54. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin. Pharmacol. Ther. 2008; 84(6):704-709.
55. Muto M, Onogawa T, Suzuki T, Ishida T, Rikiyama T, Katayose Y, et al. Human liverspecific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci. 2007;98(10):1570-1576.
56. Lee W, Belkhiri A, LockhartAC, Merchant N, Glaeser H, Harris EI, et al. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res. 2008; 68(24):10315-10323.
57. Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. British Journal of Urology International 2008;102(5):617-621.
58. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, et al. Rapid screening of antineoplastic candidates for the human organic anion transporterOATP1B3 substrates using fluorescent probes. Cancer Lett. 2008;260(1-2):163-169.
59. Franke RM, Scherkenbach LA, Sparreboom A. Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 2009;10(3):339-344.
60. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, et al. Dehydroepiandrosterone sulfate (DHEAS): Identification of a carrier protein in human liver and brain. FEBS Lett. 1998;424(3):173-176.
61. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 1995;109(4):1274-1282.
62. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 2007;81(3):362-370.
63. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): Implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 2005;280(10):9610-9617.
64. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 1999;27(8):866-871.
65. Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 2006;318(2):521-529.
66. Franke RM, Sparreboom A. Inhibition of imatinib transport by uremic toxins during renal failure. J. Clin. Oncol. 2008;26(25):4226-4227.
67. Bossuyt X, Muller M, Meier PJ. Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J. Hepatol. 1996;25(5):733-738.
68. van Montfoort JE, Hagenbuch B, Fattinger KE, Muller M, Groothuis GM, Meijer DK, et al. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J. Pharmacol. Exp. Ther. 1999;291(1): 147-152.
69. Briz O, Serrano MA, Rebollo N, Hagenbuch B, Meier PJ, Koepsell H, et al. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chlorocholylglycinate- platinum (II) and cis-diammine-bisursodeoxycholate-platinum (II) toward liver cells. Mol. Pharmacol. 2002;61(4):853-860.
70. Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008;38(7-8):778-801.
71. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liverspecific OATP-C. Pharm. Res. 2001;18(9):1262-1269.
72. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 2006;80(6):607-620.
73. Grube M, Reuther S, Meyer zu Schwabedissen HE, Kock K, Draber K, Ritter CA, et al. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab. Dispos. 2007;35(1):30-35.
74. Niessen J, Jedlitschky G, Grube M, Bien S, Schwertz H, Ohtsuki S, et al. Human platelets express OATP2B1, an uptake transporter for atorvastatin. Drug Metab. Dispos. 2009; 37(5):1129-1137.
75. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 2000;273(1):251-260.
76. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: A common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics 2009;19(2):129-138.
77. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of P-glycoprotein in the disposition of aliskiren. J. Clin. Pharmacol. 2008;48(11):1323-1338.
78. Seki S, Kobayashi M, Itagaki S, Hirano T, Iseki K. Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. Biochim. Biophys. Acta 2009;1788(5):911-917.
79. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 2008;36(10): 2014-2023.
80. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 2003;306(2):703-708.
81. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 2004;308(2):438-445.
82. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 2005;33(4):518-523.
83. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 2007; 24(7):1227-1251.
84. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 1997;51(6):913-921.
85. Terada T, Inui K. Gene expression and regulation of drug transporters in the intestine and kidney. Biochem. Pharmacol. 2007;73(3):440-449.
86. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol. Cell. Biol. 2001;21(16):5471-5477.
87. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 2002;302(2):510-515.
88. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol. Pharmacol. 2003;63(4):844-848.
89. Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell. Biol. 2003;23(21):7902-7908.
90. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 2004;308(1):2-9.
91. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002;12(8):591-595.
92. Saito S, Iida A, Sekine A, Ogawa C, Kawauchi S, Higuchi S, et al. Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J. Hum. Genet. 2002;47(11):576-584.
93. Itoda M, Saito Y, Maekawa K, Hichiya H, Komamura K, Kamakura S, et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab. Pharmacokinet. 2004;19(4):308-312.
94. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 2007;117(5):1422-1431.
95. Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC, et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab. Dispos. 2007;35(4):667-675.
96. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. USA 2003;100(10):5902-5907.
97. Takeuchi A, Motohashi H, Okuda M, Inui K. Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metab. Pharmacokinet. 2003;18(6):409-412.
98. Ciarimboli G. Organic cation transporters. Xenobiotica 2008;38(7-8):936-971.
99. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110(8):2828-2837.
100. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 2004;104(12):3739-3745.
101. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther. 2008;83(2):258-264.
102. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): Implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112(8):3348-3354.
103. Zach O, Krieger O, Foedermayr M, Zellhofer B, Lutz D. OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. Leuk. Lymphoma 2008;49(11):2222-2223.
104. Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, et al. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm. Res. 2008;25(4):827-835.
105. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications. Clin. Cancer Res. 2008;14(12):3881-3888.
106. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, et al. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res. 2008;14(10):3141-3148.
107. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112(5):2024-2027.
108. Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters. Drug Resist. Updat. 2005; 8(1-2):15-26.
109. Schneider E, Machavoine F, Pleau JM, Bertron AF, Thurmond RL, Ohtsu H, et al. Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. J. Exp. Med. 2005;202(3):387-393.
110. Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, et al. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J. Pharmacol. Exp. Ther. 2008;324(2):558-567.
111. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab. Dispos. 2008;36(8):1616-1623.
112. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab. Dispos. 2000;28(3):329-334.
113. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16(7):871-881.
114. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, et al. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J. Biol. Chem. 1998;273(47):30915-30920.
115. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J. Pharmacol. Exp. Ther. 1998; 287(2):800-805.
116. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 2002;13(4):866-874.
117. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, et al. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 2002;303(2): 534-539.
118. Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM. Interactions of ntetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm. Res. 2002;19(8):1244-1247.
119. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002;12(5):395-405.
120. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 2002;136(6):829-836.
121. Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm. Res. 2004;21(6):976-981.
122. Okuda M, Saito H, Urakami Y, Takano M, Inui K. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem. Biophys. Res. Commun. 1996;224(2):500-507.
123. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 2007;74(3):477-487.
124. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol. 2005;70(12):1823-1831.
125. Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. 2006;95(1):25-36.
126. Fukushima-Uesaka H, Maekawa K, Ozawa S, Komamura K, Ueno K, Shibakawa M, et al. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab. Pharmacokinet. 2004; 19(3):239-244.
127. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine. Pharmacogenet. Genomics 2008;18(7):637-645.
128. Song IS, Shin HJ, Shin JG. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes. Xenobiotica 2008;38(9):1252-1262.
129. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther. 2008;84(5):559-562.
130. Zolk O, Solbach TF, Konig J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala H Ser. Drug Metab. Dispos. 2009; 37(6):1312-1318.
131. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother. Pharmacol. 2008;61(6):903-909.
132. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994-1007.
133. Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity: Insights into mechanism. Int. J. Androl. 1987;10(1):325-346.
134. Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004; 66(1):196-202.
135. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 2008;14(12):3875-3880.
136. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 2006;319(2):879-886.
137. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005;167(6):1477-1484.
138. Grover B, Buckley D, Buckley AR, Cacini W. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J. Pharmacol. Exp. Ther. 2004;308(3):949-956.
139. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006; 66(17):8847-8857.
140. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 2009;296(3):F505-F511.
141. Lazar A, Zimmermann T, Koch W, Grundemann D, Schomig A, Kastrati A, et al. Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension. Clin. Exp. Hypertens. 2006;28(7):645-653.
142. Schomig E, Lazar A, Grundemann D. Extraneuronal monoamine transporter and organic cation transporters 1 and 2: A review of transport efficiency. Handbooks Exp. Pharmacol. 2006;(175):151-180.
143. Taubert D, Grimberg G, Stenzel W, Schomig E. Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons. PLoS ONE 2007;2(4):e385.
144. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl. J. Med. 2008;359(15):1577-1589.
145. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 2008;83(2):273-280.
146. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001;108(8):1167-1174.
147. Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, et al. Disposition of metformin (N, N-dimethylbiguanide) in man. Clin. Pharmacol. Ther. 1978;24(6):683-693.
148. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. 1981; 12(2):235-246.
149. Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 2003;13(9):581-584.
150. Yin OQ, Tomlinson B, Chow MS. Variability in renal clearance of substrates for renal transporters in chinese subjects. J. Clin. Pharmacol. 2006;46(2):157-163.
151. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet. 2005;20(5):379-386.
152. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm. Res. 2005;22(2):255-259.
153. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J. Hum. Genet. 2007;52(2):117-122.
154. Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, et al. Reduced function SLC22A1 polymorphisms encoding Organic Cation Transporter 1 (OCT1) and glycaemic response to metformin: A Go-DARTS study. Diabetes 2009; 58(6):1434-1439.
155. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 2006;112(2):457-473.
156. Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, et al. Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998;91(5):1749-1756.
157. Schaefer M, Roots I, Gerloff T. In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet. Genomics 2006;16(12):855-861.
158. Ishikawa T, Sakurai A, Kanamori Y, Nagakura M, Hirano H, Takarada Y, et al. Highspeed screening of human ATP-binding cassette transporter function and genetic polymorphisms: New strategies in pharmacogenomics. Methods Enzymol. 2005;400:485-510.
159. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001;70(2):189-199.
160. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 2002;62(1):1-6.
161. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002; 359(9300):30-36.
162. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000;97(7):3473-3478.
163. Xu P, Jiang ZP, Zhang BK, Tu JY, Li HD. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology 2008;82(3):221-227.
164. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315(5811):525-528.
165. Wang D, Johnson AD, Papp AC, Kroetz DL, SadeeW. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics 2005;15(10):693-704.
166. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: Functional relevance to pharmacokinetics of digoxin. Pharm. Res. 2002;19(10):1581-1585.
167. Mosyagin I, Runge U, Schroeder HW, Dazert E, Vogelgesang S, Siegmund W, et al. Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 2008;49(9):1555-1561.
168. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 2002;72(5):572-583.
169. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 2002; 25(10):1356-1359.
170. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002;12(6):451-457.
171. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 2002;71(4):297-303.
172. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: A critical review and recommendations for future research. Pharmacogenomics J 2007;7(3):154-179.
173. Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van dH, I, van Schaik RH, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet. Genomics 2008;18(4):299-305.
174. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. 2003; 58(12):809-812.
175. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. Modulation of steadystate kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 2002;72(5):584-594.
176. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 2002;54(6):610-616.
177. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 2001;18(10):1400-1404.
178. Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br. J. Clin. Pharmacol. 2005;60(2):159-171.
179. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, et al. Avariant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 2004;76(5):418-427.
180. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 2002;53(5):526-534.
181. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin. Pharmacol. Ther. 2005;78(2):191-201.
182. Foote CJ, Greer W, Kiberd B, Fraser A, Lawen J, Nashan B, et al. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007;83(10):1380-1384.
183. Foote CJ, Greer W, Kiberd BA, Fraser A, Lawen J, Nashan B, et al. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients. Transplant. Proc. 2006;38(9):2847-2849.
184. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 2003;43(6):555-564.
185. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin. Exp. Pharmacol. Physiol. 2006;33(11):1093-1098.
186. Mai I, Stormer E, Goldammer M, Johne A, Kruger H, Budde K, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J. Clin. Pharmacol. 2003;43(10):1101-1107.
187. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13(2):89-95.
188. Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporinepharmacokinetics inhealthysubjects.Ther.DrugMonit.2002;24(3):400-404.
189. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 2001;47(6):1048-1052.
190. Anglicheau D, Thervet E, Etienne I, Hurault DL, Le Meur Y, Touchard G, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. 2004;75(5):422-433.
191. Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008;68(13):4983-4989.
192. Jiang ZP, Wang YR, Xu P, Liu RR, Zhao XL, Chen FP. Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin. Pharmacol. Toxicol. 2008;103(5):433-444.
193. Sakaeda T. MDR1 genotype-related pharmacokinetics: Fact or fiction? Drug Metab. Pharmacokinet. 2005;20(6):391-414.
194. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650-1654.
195. Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistanceassociated protein 1 (MRP1/ABCC1). Pflugers Arch. 2007;453(5):621-641.
196. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol. 2005;59(4):415-424.
197. Sharom FJ. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 2008;9(1):105-127.
198. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD (P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112(24):3754-3762.
199. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2007;453(5):643-659.
200. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 2006;25(4):231-259.
201. Sai K, Saito Y, Itoda M, Fukushima-Uesaka H, Nishimaki-Mogami T, Ozawa S, et al. Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab. Pharmacokinet. 2008;23(2):139-147.
202. Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007;7(1):56-65.
203. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet. Genomics 2008;18(4):357-365.
204. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, et al. Variable expression of MRP2 (ABCC2) in human placenta: Influence of gestational age and cellular differentiation. Drug Metab. Dispos. 2005;33(7):896-904.
205. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 2006;44(1):62-74.
206. Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, et al. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. 2004;21(5):742-748.
207. Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, et al. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol. Pharm. Bull. 2008;31(11):2137-2142.
208. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, et al.AssociationsofABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007;110(1):138-147.
209. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J. Clin. Pharmacol. 2007;63(12):1161-1169.
210. Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther. 2006;80(5):468-476.
211. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study. J. AIDS 2006;42(4):441-449.
212. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007;132(1):272-281.
213. Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics 2007; 17(6):403-415.
214. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 2002; 82(2):193-201.
215. Fukushima-Uesaka H, Saito Y, Maekawa K, Hasegawa R, Suzuki K, Yanagawa T, et al. Genetic variations of the ABC transporter gene ABCC3 in a Japanese population. Drug Metab. Pharmacokinet. 2007;22(2):129-135.
216. Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004;14 (3):155-164.
217. Lee YM, Cui Y, Konig J, Risch A, Jager B, Drings P, et al. Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 2004;14(4):213-223.
218. Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, et al. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J. Hum. Genet. 2002;47(4):147-171.
219. Kobayashi K, Ito K, Takada T, Sugiyama Y, Suzuki H. Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3. Pharmacogenet. Genomics 2008;18(9):823-833.
220. Doerfel C, Rump A, Sauerbrey A, Gruhn B, Zintl F, Steinbach D. In acute leukemia, the polymorphism -211C>T in the promoter region of the multidrug resistance-associated protein 3 (MRP3) does not determine the expression level of the gene. Pharmacogenet. Genomics 2006;16(2):149-150.
221. Gradhand U, Tegude H, Burk O, Eichelbaum M, Fromm MF, Konig J. Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene. Life Sci. 2007;80(16):1490-1494.
222. Muller PJ, Dally H, Klappenecker CN, Edler L, Jager B, Gerst M, et al. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int. J. Cancer 2009;124(7):1669-1674.
223. Ritter CA, Jedlitschky G, Meyer Zu SH, Grube M, Kock K, Kroemer HK. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev. 2005;37(1):253-278.
224. Jedlitschky G, Tirschmann K, Lubenow LE, Nieuwenhuis HK, Akkerman JW, Greinacher A, et al. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 2004;104(12):3603-3610.
225. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003;38(2):374-384.
226. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: Putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 2002; 13(3):595-603.
227. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-Dglucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6- thioguanine. J. Biol. Chem. 2001;276(36):33747-33754.
228. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 2000; 275(39):30069-30074.
229. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, et al. The human multidrug resistance protein 4 (MRP4, ABCC4): Functional analysis of a highly polymorphic gene. J. Pharmacol. Exp. Ther. 2008;325(3):859-868.
230. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIVinfected patients. J. AIDS 2008;47(3):298-303.
231. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin. Pharmacol. Ther. 2008;83(2):265-272.
232. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998;95(26):15665-15670.
233. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, et al. Dominantnegative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer 2002;97(5): 626-630.
234. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 2008;23(4):223-235.
235. Gradhand U, Kim RB. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab. Rev. 2008;40(2):317-354.
236. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, et al. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ ABCP1). Cancer Biol. Ther. 2002;1(6):696-702.
237. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 2002;1(8):611-616.
238. Tamura A, Wakabayashi K, Onishi Y, Takeda M, Ikegami Y, Sawada S, et al. Reevaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci. 2007;98(2):231-239.
239. Koshiba S, An R, Saito H, Wakabayashi K, Tamura A, Ishikawa T. Human ABC transporters ABCG2 (BCRP) and ABCG4. Xenobiotica 2008;38(7-8):863-888.
240. Hardwick LJ, Velamakanni S, van Veen HW. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br. J. Pharmacol. 2007;151(2):163-174.
241. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther. 2007;6(3):432-438.
242. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer. Inst. 2006; 98(23):1739-1742.
243. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta. 2006;373(1-2):99-103.
244. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin. Pharmacol. Ther. 2008;84(1):95-103.
245. Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, et al. Breast cancer resistance protein (ABCG2) and drug disposition: Intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet. Genomics 2008;18(5):439-448.
246. Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, et al. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Exp. Clin. Transplant. 2006;4(1):416-419.
247. Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, et al. The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br. J. Clin. Pharmacol. 2008;66(2):233-239.
248. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, et al. Hoosier oncology group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin. Cancer Res. 2006;12(20 Pt. 1):6094-6099.
249. Erdilyi DJ, Kamory E, Csokay B, Andrikovics H, Tordai A, Kiss C, et al. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. Pharmacogenomics J. 2008; 8(5):321-327.
250. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 2005;56(2):161-172.
251. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer. 2004;109(2):238-246.
252. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 2004;21(10):1895-1903.
253. Furukawa T, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, Osawa Y, et al. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm. Res. 2009;26(2):469-479.
254. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 2005;33(1):94-101.
255. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003;13(1):19-28.
256. Takada T, Weiss HM, Kretz O, Gross G, Sugiyama Y. Hepatic transport of PKI166, an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class, and its main metabolite, ACU154. Drug. Metab. Dispos. 2004;32(11):1272-1278.
257. Lu WJ, Tamai I, Nezu J, Lai ML, Huang JD. Organic anion transporting polypeptide-C mediates arsenic uptake in HEK-293 cells. J. Biomed. Sci. 2006;13(4):525-533.
258. Lau YY, Okochi H, Huang Y, Benet LZ. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J. Pharmacol. Exp. Ther. 2006;316(2):762-771.
259. Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller Tet al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin. Pharmacol. Ther. 2006;79(3):186-196.
260. Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug.Metab.Dispos. 2007;35(8):1400-1407.
261. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Ther. 2007;81(3):414-419.
262. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug. Metab. Dispos. 2005;33(5):676-682.
263. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 2004;311(1):228-236.
264. Meier-Abt F, Faulstich H, Hagenbuch B. Identification of phalloidin uptake systems of rat and human liver. Biochim. Biophys. Acta. 2004;1664(1):64-69.
265. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D et al. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther. 2006;318(1):395-402.
266. Oswald S, Konig J, Lutjohann D, Giessmann T, Kroemer HK, Rimmbach C et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet. Genomics 2008;18(7):559-568.
267. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T et al. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug. Metab. Dispos. 2006;34(5):862-869.
268. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug. Metab. Dispos. 2007;35(12):2166-2176.
269. Fehrenbach T, Cui Y, Faulstich H, Keppler D. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn. Schmiedebergs. Arch. Pharmacol. 2003;368(5):415-420.
270. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 2004;311(1):139-146.
271. Fujino H, Nakai D, Nakagomi R, Saito M, Tokui T, Kojima J. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 2004;54(7):382-388.
272. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. 2001;297(3):861-867.
273. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem. 2002; 277(8):6497-6503.
274. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002;36(1):164-172.
275. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 2003;304(1):223-228.
276. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 2004;75(5):455-463.
277. Sakamoto S, Kusuhara H, Horie K, Takahashi K, Baba T, Ishizaki J et al. Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of methyl 1- (3, 4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6, 7, 8-trimethoxy-2-naphthoat e (S-8921) glucuronide, a pharmacologically active metabolite of S-8921. Drug. Metab. Dispos. 2008;36(8):1553-1561.
278. Sakamoto K, Mikami H, Kimura J. Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres. Br. J. Pharmacol. 2008;154(7):1482-1490.
279. Tsuda-Tsukimoto M, Maeda T, Iwanaga T, Kume T, Tamai I. Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm. Res. 2006;23(11):2646-2656.
280. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J et al. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug. Metab. Dispos. 2004;32(3):291-294.
281. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug. Metab. Dispos. 2006;34 (7):1247-1254.
282. Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol. Sci. 2006;91(1):140-149.
283. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 2000; 275(30):23161-23168.
284. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug. Metab. Dispos. 2005;33(10):1477-1481.
285. Baldes C, Koenig P, Neumann D, Lenhof HP, Kohlbacher O, Lehr CM. Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3). Eur. J. Pharm. Biopharm. 2006;62(1):39-43.
286. Fischer WJ, Altheimer S, Cattori V, Meier PJ, Dietrich DR, Hagenbuch B. Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin. Toxicol. Appl. Pharmacol. 2005;203(3):257-263.
287. Komatsu M, Furukawa T, Ikeda R, Takumi S, Nong Q, Aoyama K et al. Involvement of mitogen-activated protein kinase signaling pathways in microcystin-LR-induced apoptosis after its selective uptake mediated by OATP1B1 and OATP1B3. Toxicol. Sci. 2007;97(2):407-416.
288. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 2002;300(3):918-924.
289. Nies AT, Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn. Schmiedebergs. Arch. Pharmacol. 2008;376(6):449-461.
290. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E et al.Aspecies difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 2005;315(1):337-345.
291. Ming X, Ju W, Wu H, Tidwell RR, Hall JE, Thakker DR. Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug. Metab. Dispos. 2009;37(2):424-430.
292. Kang HJ, Lee SS, Lee CH, Shim JC, Shin HJ, Liu KH et al. Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters. Drug. Metab. Dispos. 2006;34(7):1145-1151.
293. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P et al. Transport of Lamivudine (3TC) and High-Affinity Interaction of Nucleoside Reverse Transcriptase InhibitorsWith Human Organic Cation Transporters 1 2, and 3. J. Pharmacol. Exp. Ther. 2009.
294. Sato T, Masuda S, Yonezawa A, Tanihara Y, Katsura T, Inui K. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem. Pharmacol. 2008;76 (7):894-903.
295. Bourdet DL, Pritchard JB, Thakker DR. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther. 2005;315(3):1288-1297.
296. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. 1998;54 (2):342-352.
297. Biermann J, Lang D, Gorboulev V, Koepsell H, Sindic A, Schroter R et al. Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am. J. Physiol. Cell. Physiol. 2006;290(6):C1521-C1531.
298. Chen Y, Zhang S, Sorani M, Giacomini KM. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J. Pharmacol. Exp. Ther. 2007;322(2):695-700.
299. Thuerauf N, Fromm MF. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur. Arch. Psychiatry Clin. Neurosci. 2006;256(5):281-286.
300. Deeken JF, Figg WD, Bates SE, Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer. Drugs. 2007;18(2):111-126.
301. Kock K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin. Pharmacokinet. 2007;46(6):449-470.
302. Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet. Genomics. 2008; 18(5):424-433.
303. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE et al. Influence of the organic aniontransporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 2008;59(1):69-75.
304. He YJ, Zhang W, Chen Y, Guo D, Tu JH, Xu LY et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T H C polymorphism. Clin. Chim. Acta. 2009;405(1-2):49-52.
305. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol. 2008;48(3):311-321.
306. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br. J. Clin. Pharmacol. 2008;65(1):78-86.
307. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 2005; 78(4):388-399.
308. Niemi M, Kivisto KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF et al. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics. 2006;16(8):565-568.
309. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics. 2005;15(5):303-309.
310. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 2006; 80(4):356-366.
311. Suwannakul S, Ieiri I, Kimura M, Kawabata K, Kusuhara H, Hirota T et al. Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J. Hum. Genet. 2008;53(10):899-904.
312. Takane H, Miyata M, Burioka N, Kurai J, Fukuoka Y, Suyama H et al. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther. Drug. Monit. 2007;29(5):666-668.
313. Zhang W, He YJ, Gan Z, Fan L, Li Q, Wang A et al. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin. Exp. Pharmacol. Physiol. 2007;34(12):1240-1244.
314. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D et al. The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin. Clin. Pharmacol. Ther. 2009;86(3):299-306.
315. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics. J. 2009;9(4):242-247.
316. Bernsdorf A, Giessmann T, Modess C, Wegner D, Igelbrink S, Hecker U et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006; 61(4):440-450.
317. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther. 2006;80(2):192-201.
318. Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 2009;49(2):196-204.
319. Yamaguchi H, Hishinuma T, Endo N, Tsukamoto H, Kishikawa Y, Sato M et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int. J. Gynecol. Cancer. 2006;16(3):979-985.
320. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006;82(8):1074-1084.
321. Niemi M, Arnold KA, Backman JT, Pasanen MK, Godtel-Armbrust U, Wojnowski L et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistanceassociated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet. Genomics. 2006;16(11):801-808.
322. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c. 421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 2007;98(9):1461-1467.
323. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 2004;76(1):38-44.
324. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD et al. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther. 2005;4 (6):650-658.
325. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin. Pharmacol. Ther. 2004Jan; 75(1):101-9.